Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 10 Endocrine 2 NET 1 Genitourinary 1

Conditions

Neuroendocrine Prostate Cancer 1

Interventions

pembrolizumab 182 Magnetic Resonance Spectroscopy 161 Specimen Handling 134 enzalutamide 125 Nivolumab 118 Gemcitabine 96 Docetaxel 92 Radiosurgery 91 Prednisone 81 Androgen Antagonists 81 Abiraterone Acetate 79 Radiotherapy 75 apalutamide 66 Cisplatin 65 darolutamide 62 Ipilimumab 61 Biopsy 61 abiraterone 57 cabozantinib 55 Carboplatin 55 Leuprolide 52 enfortumab vedotin 50 Radiation 47 Pluvicto 45 Standard of Care 44 atezolizumab 41 Surveys and Questionnaires 38 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37 X-Rays 37 avelumab 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

AMG 757 × Genitourinary × 1 year × Clear all

NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed

41 enrolled 19 charts

EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡